New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2014
05:55 EDTKINKindred Biosciences downgraded to Neutral from Buy at Roth Capital
Roth Capital downgraded Kindred Biosciences citing valuation following the company's Q4 results but raised its price target for shares to $25 from $20.
News For KIN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2014
10:31 EDTKINKindred Biosciences management to meet with Guggenheim
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use